Huadong Medicine Overview
- Year Founded
-
1993
- Status
-
Public
- Employees
-
19,095
- Stock Symbol
-
000963
- Investments
-
14
- Share Price
-
$3.73
- (As of Friday Closing)
Huadong Medicine General Information
Description
Huadong Medicine Co Ltd is engaged in the production and sales of antibiotics, proprietary Chinese medicine, chemical synthetic medicine, and genetic engineering drug products. The company mainly operates its business through three segments. The Manufacturing Business segment is engaged in the research and development, production, and marketing of specialized medicines, medicines for chronic diseases, as well as special medicines. The Commercial Business segment is engaged in the sales of medicines, medical devices, ginseng, and antler pieces. The International Medical Beauty Business segment is engaged in the production and sales of regeneration products, hyaluronic acids, and botulinum toxin products.
Contact Information
Website
www.eastchinapharm.comCorporate Office
- Number 858
- Mogan Shan Road
- Hangzhou, Zhejiang 310011
- China
Corporate Office
- Number 858
- Mogan Shan Road
- Hangzhou, Zhejiang 310011
- China
Huadong Medicine Stock Performance
As of 20-Nov-2026, Huadong Medicine’s stock price is $3.73. Its current market cap is $6.54B with 1.75B shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.73 | $3.81 | $3.70 - $6.09 | $6.54B | 1.75B | 15.3M | $0.28 |
Huadong Medicine Financials Summary
As of 30-Sep-2026, Huadong Medicine has a trailing 12-month revenue of $6.38B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 6,779,649 | 9,642,089 | 8,062,337 | 10,043,093 |
| Revenue | 6,378,783 | 6,064,535 | 5,840,142 | 5,741,975 |
| EBITDA | 580,103 | 702,233 | 718,205 | 607,744 |
| Net Income | 498,832 | 474,786 | 489,461 | 401,259 |
| Total Assets | 5,978,334 | 5,579,493 | 5,188,839 | 4,727,219 |
| Total Debt | 309,452 | 296,086 | 373,829 | 248,170 |
Huadong Medicine Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Huadong Medicine Comparisons
Industry
Financing
Details
Huadong Medicine Competitors (22)
One of Huadong Medicine’s 22 competitors is GSK, a Corporation company based in London, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| GSK | Corporation | London, United Kingdom | ||||
| Roche | Corporation | Basel, Switzerland | ||||
| Teva Pharmaceutical Industries | Corporation | Tel Aviv, Israel | ||||
| Biocon | Formerly PE-Backed | Bengaluru, India | ||||
| Aurobindo Pharma | Corporation | Hyderabad, India |
Huadong Medicine Signals
Huadong Medicine Investments & Acquisitions (14)
Huadong Medicine’s most recent deal was a Later Stage VC with Ashvattha Therapeutics for . The deal was made on 13-Jan-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Ashvattha Therapeutics | 13-Jan-2025 | Later Stage VC | Drug Discovery | ||
| Hengba Pharmaceutical | 21-Jul-2024 | Merger/Acquisition | Pharmaceuticals | ||
| Chongqing Yuyan | 14-Nov-2023 | Early Stage VC | Other Pharmaceuticals and Biotechnology | ||
| Jinannong Group | 31-May-2023 | Merger/Acquisition | Other Agriculture | ||
| Huaren Technology | 08-Aug-2022 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology |
Huadong Medicine ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
30.89 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Huadong Medicine Exits (1)
Huadong Medicine’s most recent exit was on 09-Oct-2020 from Qyuns. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Qyuns | 09-Oct-2020 | Completed |
|
Huadong Medicine Affiliates
Subsidiaries (8)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Huachang Hi-Tech | Anshan, China | 2015 | |
| Doer Biologics | Hangzhou, China | 2014 | |
| Huaren Technology | Wuhu, China | 2006 | |
| Jinannong Group | Nanjing, China | 1996 | |
| Hengba Pharmaceutical | Guiyang, China | 1995 |
Huadong Medicine FAQs
-
When was Huadong Medicine founded?
Huadong Medicine was founded in 1993.
-
Where is Huadong Medicine headquartered?
Huadong Medicine is headquartered in Hangzhou, China.
-
What is the size of Huadong Medicine?
Huadong Medicine has 19,095 total employees.
-
What industry is Huadong Medicine in?
Huadong Medicine’s primary industry is Pharmaceuticals.
-
Is Huadong Medicine a private or public company?
Huadong Medicine is a Public company.
-
What is Huadong Medicine’s stock symbol?
The ticker symbol for Huadong Medicine is 000963.
-
What is the current stock price of Huadong Medicine?
As of 20-Nov-2026 the stock price of Huadong Medicine is $3.73.
-
What is the current market cap of Huadong Medicine?
The current market capitalization of Huadong Medicine is $6.54B.
-
What is Huadong Medicine’s current revenue?
The trailing twelve month revenue for Huadong Medicine is $6.38B.
-
Who are Huadong Medicine’s competitors?
GSK, Roche, Teva Pharmaceutical Industries, Biocon, and Aurobindo Pharma are some of the 22 competitors of Huadong Medicine.
-
What is Huadong Medicine’s annual earnings per share (EPS)?
Huadong Medicine’s EPS for 12 months was $0.28.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process